Difference between revisions of "Real-time pharmacy surveillance and clinical decision support to reduce adverse drug events in acute kidney injury – a randomized, controlled trial."

From Clinfowiki
Jump to: navigation, search
(Conclusion)
Line 11: Line 11:
  
 
= Conclusion =
 
= Conclusion =
McCoy et al., (2012) found that “while CDS is effective at preventing (potential [Adverse drug event]s) pADEs and ADEs in patients with AKI, further research is necessary to determine whether surveillance can improve CDS performance” (p.227).  
+
McCoy et al., (2012) found that “while CDS is effective at preventing (potential [[Adverse drug event]]s) pADEs and ADEs in patients with AKI, further research is necessary to determine whether surveillance can improve CDS performance” (p.227).  
 
This article was an enjoyable read; it is interesting how CDS is well accepted by many to improve clinical outcomes but yet proving it with statistics for many has remained quite elusive.
 
This article was an enjoyable read; it is interesting how CDS is well accepted by many to improve clinical outcomes but yet proving it with statistics for many has remained quite elusive.
  

Revision as of 19:55, 25 March 2015

This is a review of McCoy, A.B., Cox, Z.L., Neal, E.B., Waitman, L.R., Peterson, N.B., Bhave, G., Siew, E.D., Danciu, I., Lewis, J.B. and Peterson, J.F. (2012). “Real-time pharmacy surveillance and clinical decision support to reduce adverse drug events in acute kidney injury – a randomized, controlled trial.” [1]

Background

Medications comprise the largest source of medical errors in the healthcare industry today. Therefore building CDS systems to monitor the ordering and dispensing of prescription drugs could prevent significant morbidity, mortality and inefficiencies in hospitals around the world. Polypharmacy is not uncommon in today’s healthcare arena as people live longer with chronic disease often entailing much comorbidity. Numerous drugs are used to manage one individual’s health and drug-drug interactions can be all too common.

Methods

McCoy et al., (2012) examined whether adding pharmacy surveillance to a clinical practice already utilizing CDS alert software could reduce adverse drug events and/ or avoid occurrences of drug induced kidney dysfunction to patients with underlying renal disease. The authors carried out a randomized clinical trial with 396 patients who were admitted during a three month period. The intervention group received an extra look in by a pharmacist for medication events associated with declining renal function.

Results

McCoy and colleagues found no added benefit or reduction in kidney functioning between the control versus intervention groups. This study was fishing for a potential intervention which would potentially improve patient safety by reducing ADEs. When comparing provider response to abnormal serum creatinine due to active medications McCoy et al., (2012) found no “statistically significant differences between the control and intervention groups” (p.225).

Conclusion

McCoy et al., (2012) found that “while CDS is effective at preventing (potential Adverse drug events) pADEs and ADEs in patients with AKI, further research is necessary to determine whether surveillance can improve CDS performance” (p.227). This article was an enjoyable read; it is interesting how CDS is well accepted by many to improve clinical outcomes but yet proving it with statistics for many has remained quite elusive.

References

  1. McCoy, A.B., Cox, Z.L., Neal, E.B., Waitman, L.R., Peterson, N.B., Bhave, G., Siew, E.D., Danciu, I., Lewis, J.B. and Peterson, J.F. (2012). Real-time pharmacy surveillance and clinical decision support to reduce adverse drug events in acute kidney injury – a randomized, controlled trial. Applied Clinical Informatics; 3: 221–238.